Research on animal models has illustrated that targeted proteasome inhibition could potentially stabilize Nrf2, leading to the enhancement of antioxidant defenses, a reduction in ROS levels, and a decrease in renal fibrosis. The gene discussed is NFE2L2; the disease is renal fibrosis.